We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cello Health Plc | LSE:CLL | London | Ordinary Share | GB00B0310763 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 161.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLL
RNS Number : 6423A
Cello Health PLC
22 January 2020
22 January 2020
Cello Health plc
("Cello" or the "Company")
Block Listing Update
Total Voting Rights
The Company notifies that, since the date of its most recent block listing update, a total of 1,232,928 new ordinary shares of 10p each in the share capital of the Company have been issued and allotted (pursuant to the Company's PSP Option Scheme 2010, its Approved Share Option Plan 2009 and its Unapproved Scheme 2010) and admitted to trading in accordance with the block listing. An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below.
As at today's date, Cello's issued share capital comprises 106,778,473 ordinary shares of 10 pence each ("Ordinary Shares"), of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company is therefore 106,325,473 Ordinary Shares, which may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquires
Cello Health 020 7812 8460 Mark Scott, Chief Executive Mark Bentley, Group Finance Director Cenkos Securities 020 7397 8900 Giles Balleny Harry Hargreaves Buchanan 020 7466 5000 Mark Court Jamie Hooper Sophie Wills
BLOCK LISTING SIX MONTHLY RETURN
Name of applicant: Cello Health plc Name of scheme: PSP Option Scheme 2010, Approved Share Option Plan 2009 and Unapproved Scheme 2010 ------------------------------------------- Period of return: From: 23 May 2019 To: 21 January 2020 ---------- ------------------ ------ --------------- Balance of unallotted securities under scheme(s) from previous return: 2,918,747 ------------------------------------------- Plus: The amount by which the - block scheme(s) has been increased since the date of the last return (if any increase has been applied for): ------------------------------------------- Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): (1,232,928) ------------------------------------------- Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1,685,819 ------------------------------------------- Name of contact: Mark Bentley, Group Finance Director ------------------------------------------- Telephone number of contact: 020 7812 8460 -------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BLRFLFVRLAIFFII
(END) Dow Jones Newswires
January 22, 2020 11:40 ET (16:40 GMT)
1 Year Cello Health Chart |
1 Month Cello Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions